FGFR1 amplification is not a reliable biomarker for FGFR inhibitors in treating lung squamous cell carcinoma due to its limited efficacy with only 7% to 11% of patients exhibiting durable responses in clinical trials (82, 83). Here, FGFR1 is linked to squamous cell lung carcinoma.